Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva with Chemoradiotherapy in Esophageal Carcinoma
NCT00686114Phase 3Unknown
- Sponsor
- Wenzhou Medical University
- Start
- May 2008
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of erlotinib in esophageal carcinoma (4 arms), sponsored by Wenzhou Medical University. Primary endpoint: Overall Survival at 5 years. Status: unknown.
02
Drugs
erlotinib
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT00686114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686114.